Carcinoma, Breast
Conditions
Keywords
CpG 7909 subcutaneous injection combination with Herceptin® metastatic breast cancer.
Brief summary
To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.
Interventions
DRUG0.04 mg/kg CpG 7909
0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
DRUGHerceptin®
Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
DRUG0.08 mg/kg CpG 7909
0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
DRUG0.12 mg/kg CpG 7909
0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
DRUG0.16 mg/kg CpG 7909
0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed breast cancer with metastases * Tumor that has overexpression of HER2 as documented by being either FISH-positive or HER2/neu 3+ confirmed by immunohistochemistry * Patients may have had up to three prior chemotherapy regimens for metastatic disease, which may have been given in combination with Herceptin® and which may have been discontinued due to toxicities. In addition, patients may have had adjuvant chemotherapy. * Phase II only: Must have measurable disease by RECIST criteria (defined in section 8) with at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques, or as \> 10 mm with spiral CT scan
Exclusion criteria
* Any prior therapy with anthracycline + Herceptin® concurrently * Significant cardiovascular disease (e.g., NYHA class 3 congestive heart failure, myocardial infarction within the past 6 months, unstable angina; coronary angioplasty within the past 6 months, uncontrolled atrial or ventricular cardiac arrhythmias) or left ventricular ejection fraction \< 50% * Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, autoimmune thrombocytopenia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase I: To evaluate the safety and tolerability of several dose levels of CPG 7909 (up to a maximum of 0.16 mg/kg) and to determine the maximum tolerated dose (MTD)* of CPG 7909 in combination with Herceptin® | 24 weeks |
| Phase II: To evaluate tumor response and safety of CPG 7909 (at the MTD as determined in Phase I) in combination with Herceptin® in patients with metastatic breast cancer. | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Phase I To evaluate tumor response, duration of response, time to disease progression, ECOG performance status, and survival time. | 24 weeks |
| Phase II To evaluate duration of response, time to disease progression, ECOG performance status, and survival time. | 24 weeks |
Countries
United States
Outcome results
None listed